Key Takeaways
- Steady quarter, H2 rebound promised: Revenue held at Rs.342 crores, above 85% of historical run rate, while management guided a return to the Rs.400+ crore quarterly run rate by Q4, possibly Q3.
- Gross margin recovery underway: Gross margin improved 270 bps QoQ to 44.2%, with H2 exit targeted at 50%, driven by product mix and base business actions.
- Vizag unlocks are regulatory, not demand: CEP approval received, China DMF approved for Puducherry, and US DMF amended to add Vizag, but full utilization waits on US FDA inspection now expected in H2 FY2024.
- CRAMS ambition is real but early: A North America CRAMS head is onboarded and management wants the segment "bigger than single digit," yet material traction is not expected until FY2024.
- What to watch next quarter: Whether the Q3 revenue advance materializes, the pace of Vizag under-recovery reduction, and any CRAMS RFP conversions from the H1 pipeline.
Revenue & Margin Trajectory
- Q2 held the line: Revenue of Rs.342 crores represented a steady performance with base business margins improving sequentially, even as H1 demand stayed below historical levels.
- Gross margin levers: The 270 bps QoQ improvement to 44.2% came from a favorable product mix within the existing base portfolio, with regulated market share holding sequentially at 66%.
- H2 exit targets: Management committed to a 50% gross margin and Rs.400+ crore quarterly revenue by Q4, with internal green shoots in the base business suggesting the revenue recovery could pull forward into Q3.
- Vizag drag: Under-recovery at the Vizag facility remained a headwind on EBITDA, with the site running at roughly 75% capacity utilization; management aims for this drag to be neutralized from Q4 onward.
- Debt trajectory: Debt reduced by Rs.12 crores in H1, with a slight further reduction expected by year-end and a normalized net debt-to-EBITDA ratio of 2.5–3x targeted by FY2024.
Jitesh Devendra: "With a focus on all the actions above, we are confident that in outgoing Q4, we will return to our historical revenue, run rate of minimum Rs.400 crores per quarter with mid-teens EBITDA margin and turning PAT positive."
Vizag Facility: Approvals, Timelines & Utilization
- Regulatory unlocks stacking up: CEP approval for ibuprofen manufacture at Vizag was received in Q2, the US DMF was amended to add Vizag as an additional site, and one major customer has already filed a PAS application referencing the site.
- Inspection timeline is the bottleneck: A prior-approval inspection (PAI) by the US FDA is expected in the next financial year, probably in H2 FY2024, triggered by ibuprofen and a couple of other products currently undergoing validations.
- Bridging the gap: Until full regulatory clearance arrives, Solara plans to supply certain products from Vizag to markets with no or minimal regulatory binding starting Q3, while new product validations initiated at the site will be filed in H2 FY2023.
- Capacity ramp path: With CEP now in hand, management estimates it will take roughly one more year to reach full-fledged capacity utilization, targeting full potential by end of FY2024; no major additional capex is expected at the site.
- Ibuprofen dual-site qualification: The company is actively talking to customers to qualify Vizag alongside Puducherry so both sites can meet demand growth for ibuprofen.
Ibuprofen & Base Business Dynamics
- Pricing stable, demand decent: Ibuprofen and other key API pricing is described as "pretty stable," with H1 demand characterized as decent but not great and similar expectations for H2; inventory levels are not a concern.
- Growth from reach, not shortage: Ibuprofen growth is coming from adding new customers and new geographies, not from any supply disruption or shortage in the market.
- China approval, delayed payoff: The CDE China approval for ibuprofen API was received after nearly three years, but commercial supplies are not expected until 2024 because customers must first take validation batches and complete their own regulatory submissions.
- Non-ibuprofen expansion: Market extensions for current products into newer geographies such as Brazil and China are expected to drive traction for non-ibuprofen APIs, with eight new market extensions filed for nine existing APIs in Q2.
- Brazil order secured: A major order for one key product from Brazil was booked in Q2, with delivery scheduled for Q3.
Jitesh Devendra: "Pricing is pretty stable on ibuprofen and on other key APIs also what we manufacture and the inventory level of ibuprofen for us as I said, in the first half, also we had seen a decent demand. I would not say a great one. This is what we are expecting in the second half and the inventory levels are not a concern at all."
CRAMS: Building a Second Leg
- North America push begins: A CRAMS head for North America was onboarded during the quarter, and management reports significant traction in the last month, with hopes of converting some RFPs submitted in H1 during H2 FY2023.
- Ambition exceeds current scale: Management was explicit that CRAMS must become "definitely a bigger piece than being a single digit" and that the intent is to grow the business, not merely maintain it at the current ~5% of revenue.
- Traction timeline: Material revenue contribution from the US CRAMS effort is expected only in FY2024, with a 3-to-4-year horizon for CRAMS to become a sizable portion of the business, supported by ongoing team building on the business development side.
- China Plus One framing: Management acknowledged that reputed CDMO players exist in China and that the China Plus One policy is a tailwind, but emphasized that outcomes ultimately depend on the company's own efforts to break through with new and existing customers.
Jitesh Devendra: "No, we want CRAMS to be definitely a bigger piece than being a single digit... we want to grow this business and not just maintain it at 5%."
Regulatory & Filing Pipeline
- Cuddalore progress: One polymer product from the Cuddalore site has been filed by a customer, taking the total pending US FDA approvals to 12.
- Brazil filings: The company is targeting three to four product filings in Brazil during the current financial year.
- R&D cadence: Solara is on track to file six new products in FY2023, with validation of new products from the Vizag site initiated and filings planned for H2.
- Lyophilization investment: A lyophilization capability has been added at the Vizag site, described as a unique capability, and is already supporting one ongoing product validation.
- Regulatory inspection catch-up: Regulatory inspections were delayed for an extended period due to COVID; action was initiated during the current quarter to address the backlog.
Guidance & Commitments
| Commitment | Specifics | Timeline |
|---|---|---|
| Quarterly revenue run rate | Return to minimum Rs.400 crores per quarter | Q4 FY2023 (possibly Q3) |
| EBITDA margin | Mid-teens EBITDA margin | Q4 FY2023 |
| PAT | Turn PAT positive | Q4 FY2023 |
| Gross margin | Exit at 50% gross margin | Q4 FY2023 |
| Vizag under-recovery | Under-recoveries to be met / neutralized | Q4 FY2023 |
| Vizag US FDA inspection | Prior-approval inspection (PAI) expected | H2 FY2024 |
| Vizag full capacity utilization | Full-fledged operations at capacity | End of FY2024 |
| Net debt-to-EBITDA | Normalized position of 2.5x to 3x | FY2024 |
| CRAMS material revenue | Traction from US efforts | FY2024 |
| Ibuprofen China commercial supplies | Commercial supplies begin | 2024 |
| CRAMS sizable portion | Become a sizable portion of the business | 3-to-4-year horizon |
| Brazil product filings | File three to four products | Current financial year (FY2023) |
| New product filings (R&D) | File six new products | Current financial year (FY2023) |
| Vizag new product filings | File validations initiated in H1 | H2 FY2023 |
| Vizag supplies to less regulated markets | Certain product supplies begin | Q3 FY2023 |
Key Metrics
| Metric | Q2 FY23 |
|---|---|
| Revenue | ₹342 cr, >85% of historical quarterly run rate |
| Gross margin | 44.2%, improved 270 bps over Q1; H1 gross margin ~42% |
| Operating EBITDA | ₹52.6 cr, 15% margin |
| Regulated market revenue share | 66%, sequentially similar |
| CRAMS revenue share | ~5% of total revenues |
| Overall capacity utilization | ~75% |
| Net debt to EBITDA (FY23 target) | ~5x by end of FY23 |
| Net debt to EBITDA (FY24 target) | 2.5x to 3x by end of FY24 |
| Term debt | ₹346 cr |
| Working capital debt | ₹600 cr |
| Debt reduction in H1 | ₹12 cr reduced |
| Expected annual debt repayment | ~₹100 cr from internal accruals |
| New market extensions filed (Q2) | 8 extensions for 9 existing APIs |
| New market extensions filed (H1) | 9 extensions for 10 existing APIs |
| New R&D programs added (FY23) | 15+ programs |
| New product filings target (FY23) | 6 products on track |
| Pending US FDA approvals (Cuddalore) | 12 total, including 1 polymer product filed by customer |
| Brazil filings | 2 total, target 3-4 in FY23 |
| Historical quarterly revenue run rate | ₹400 cr minimum, expected return by Q4 FY23 |
| Gross margin target (Q4 FY23) | Closer to 50% |
| Vizag under-recovery offset target | Q4 FY23 |
| Vizag full capacity utilization target | End of FY24 |